Suggested remit: To appraise the clinical and cost effectiveness of 177Lu-PSMA-617 within its marketing authorisation for treating prostate-specific membrane antigen (PSMA) positive, hormone-relapsed metastatic prostate cancer previously treated with androgen receptor directed therapy (ARDT) and taxane based chemotherapy.
Status In progress
Technology type Medicine
Decision Selected
Process TA
ID number 3840

Provisional Schedule

Expected publication 15 November 2023

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield


Companies sponsors Novartis Pharmaceuticals
Others Department of Health and Social Care
  NHS England
  Welsh Govenment
Patient carer groups Prostate Cancer UK
  Tackle prostate cancer
Professional groups Association of Cancer Physicians
  British Nuclear Medicine Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Bayer
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
06 September 2023 Committee meeting: 3
09 August 2023 The appraisal committee meeting scheduled for 2 August 2023 is now expected to take place on 6 September 2023.
21 February 2023 - 14 March 2023 Draft guidance: 2
12 January 2023 Committee meeting: 2
12 October 2022 - 02 November 2022 Draft guidance
04 February 2022 The timelines for this appraisal have been amended. The appraisal committee meeting is now scheduled to take place on Thursday 15 September 2022.
03 November 2021 Invitation to participate
16 July 2021 Please note that following on from advice received from the company the timelines for this appraisal have been revised. For information, we anticipate that the appraisal will now begin during early November 2021.
08 June 2021 - 06 July 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
01 September 2020 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual